The stock market is the supermarket of equities. You can shop or find the best deals and pick good stocks that are not necessarily blue-chip stocks. Some are selling below $7 today. Don’t pass up on the limited offer as the value of the stocks could very well rise very soon. These cheap stocks could be the investment of a lifetime.
Biotech stocks are risky and volatile. The success of biotech firms is anchored on positive results of clinical studies and trials of drug candidates. BELLUS Health (TSX:BLU) focuses on developing novel therapeutics for the treatment of chronic cough and other hyper-sensitization-related disorders.
The clinical-stage biopharmaceutical company has a blockbuster drug in the making. The company’s lead product candidate, BLU-5937, is for the treatment of chronic cough.
Last November, BELLUS announced positive top-line results from the clinical phase one study of BLU-5937. The drug was proven to be safe and well tolerated by patients. With a benign side effect profile demonstrated in numerous pre-clinical studies, it was found that the drug can be the best-in-class therapeutic for refractory chronic cough patients.
BELLUS has advanced to the phase two study for BLU-5937 in patients with refractory unexplained chronic cough. The top-line results are expected by mid-2020. Refractory chronic cough is a significant unmet medical need with no currently approved treatments. For $3.09, you’re invested in the future biotech champion.
Energy stock Encana (TSX:ECA)(NYSE:ECA) is trading at $5.54 and is just an inch away from the 52-week low of $5.46. The analysts’ forecasts should be encouraging to bargain shoppers. The price is predicted to increase between 147% and 279% in the next 12 months.
The energy sector had a good run earlier this year with the price even soaring to $10 before dropping to an all-time low. The drop made Encana super-cheap and a real giveaway considering the 1.7% dividend yield. However, current stockholders are not likely to sell now.
It’s not precarious to invest in the $7.8 billion company that has been profitable for the last two years. The price movement isn’t indicative of the company’s stable performance and good balance sheet. There’s a possibility that Encana could buy back shares to keep investors happy.
New kid in town
International Petroleum (TSX:IPCO) or IPC is a relatively new internationally focused, upstream oil and gas company. IPC is part of the Lundin Group of Companies, which is comprised of companies operating in the mining, oil and gas, and solar energy sectors.
This is a good time for investors to invest $5.51 and ride on the early stages of IPC’s organic growth. The company has a high-quality portfolio of assets located in Canada, Europe, and southeast Asia.
IPC turned in profits in 2017 after two years of cutting down on losses. In 2018, revenue grew by 124.25% while the bottom line increased by 356.11%. All signs point to a very promising future and the potential for long-term growth. IPC is following the Lundin Group’s unique and successful natural resource development strategy.
IPC will certainly attract value investors, as the company has yet to achieve its true value. If value investors will waste no time in purchasing the stock, then neither should you.
Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Christopher Liew has no position in any of the stocks mentioned.